ABSTRACT
Purpose COVID-19 is associated with cardiovascular complications, with right ventricular dysfunction (RVD) commonly reported. The combination of acute respiratory distress syndrome (ARDS), injurious invasive ventilation, micro/macro thrombi and the potential for direct myocardial injury create conditions where RVD is likely to occur. No study has prospectively explored the prevalence of RVD, and its association with mortality, in a cohort requiring mechanical ventilation.
Methods Prospective, multi-centre, trans-thoracic echocardiographic, cohort study of ventilated patients with COVID-19 in Scottish intensive care units. RVD was defined as the presence of severe RV dilatation and interventricular septal flattening. To explore role of myocardial injury, high sensitivity troponin and N-terminal pro B-type natriuretic peptide (NT-proBNP) were measured in all patients.
Results One hundred and twenty-one patients were recruited to COVID-RV, 118 underwent imaging and it was possible to determine the primary outcome in 112. RVD was present in seven (6.2% [95%CI; 2.5%, 12.5%]) patients. Thirty-day mortality was 85.7% in those with RVD, compared to 44.8% in those without (p=0.051). Patients with RVD were more likely to have; pulmonary thromboembolism (p<0.001), higher plateau pressure (p=0.048), lower dynamic compliance (p=0.031), higher NT-proBNP (p<0.006) and more frequent abnormal troponin (p=0.048). Abnormal NT-proBNP (OR 4.77 [1.22, 21.32], p=0.03) and abnormal Troponin (16.54 [4.98, 67.12], p<0.001) independently predicted 30-day mortality.
Conclusion COVID-RV demonstrates a prevalence of RVD in ventilated patients with COVID-19 of 6.2% and is associated with a mortality of 85.7%. Association is observed between RVD and each of the aetiological domains of; ARDS, ventilation, micro/macro thrombi and myocardial injury.
Competing Interest Statement
Colin Berry is employed by the University of Glasgow which holds consultancy and research agreements for his work with Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Causeway Therapeutics, Coroventis, Genentech, GSK, HeartFlow, Menarini, Neovasc, Siemens Healthcare, and Valo Health.
All other authors confirm no conflict of interest.
Clinical Trial
NCT04764032
Clinical Protocols
https://bmjopen.bmj.com/content/11/1/e042098
Funding Statement
This work was supported by Medical Research Scotland (grant number CVG-1730-2020). BSh is supported by the National Institute of Academic Anaesthesia / Royal College of Anaesthetists British Oxygen Company Chair of Anaesthesia Research Grant. Colin Berry receives research funding from the British Heart Foundation grant (RE/18/6134217), Chief Scientist Office, EPSRC (EP/R511705/1, EP/S030875/1), European Union (754946-2), Medical Research Council (MR/S018905/1) and UKRI (MC/PC/20014).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was gained from Scotland A Research Ethics Committee (REC reference 20/SS/0059).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
ClinicalTrials.gov Identifier: NCT04764032 (Registered 21st Feb 2021)
Declarations
Funding This work was supported by Medical Research Scotland (grant number CVG-1730-2020). BSh is supported by the National Institute of Academic Anaesthesia / Royal College of Anaesthetists British Oxygen Company Chair of Anaesthesia Research Grant. Colin Berry receives research funding from the British Heart Foundation grant (RE/18/6134217), Chief Scientist Office, EPSRC (EP/R511705/1, EP/S030875/1), European Union (754946-2), Medical Research Council (MR/S018905/1) and UKRI (MC/PC/20014).
Conflicts of interest/Competing interests (include appropriate disclosures) Colin Berry is employed by the University of Glasgow which holds consultancy and research agreements for his work with Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Causeway Therapeutics, Coroventis, Genentech, GSK, HeartFlow, Menarini, Neovasc, Siemens Healthcare, and Valo Health.
Ethics approval: Approval was gained from Scotland A Research Ethics Committee (REC reference 20/SS/0059).
Consent to participate Informed consent was obtained from all participants included in the study, or their legal representative.
Take-home message In a prospective cohort of 121 patients with COVID-19 requiring mechanical ventilation, echocardiographic evidence of right ventricular dysfunction was present in 6.2% and was associated with high mortality. There was association between right ventricular dysfunction and acute respiratory distress syndrome, mechanical ventilation, pulmonary thromboembolism and myocardial injury.
Tweet COVID-RV demonstrates #EchoFirst evidence of #RightVentricle dysfunction in ventilated #COVID-19 patients with associated high mortality
Data Availability
The data that support the findings of this study are available from the corresponding author, [BS], upon reasonable request and subject to appropriate ethical approvals.